Boston, MA -- (SBWIRE) -- 08/15/2013 -- At winstonsmallcap.com we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. Let have a Look on: (Osiris Therapeutics, Inc. (NASDAQ:OSIR), Cirrus Logic, Inc.(NASDAQ:CRUS), JinkoSolar Holding Co., Ltd. (NYSE:JKS), Merrimack Pharmaceuticals Inc (NASDAQ:MACK)
Osiris Therapeutics, Inc. (NASDAQ:OSIR) stock dropped 11.75% to $22.45. The company on August 13 said its Grafix stem-cell treatment for chronic diabetic foot ulcers met primary and secondary endpoints in a recent clinical trial that compared the product with conventional treatment. The study included 131 diabetes patients who received weekly applications of Grafix or conventional treatment. In the trial, 62% of patients receiving Grafix had complete wound closure compared with only 21% of patients who received conventional treatment.
How Should Investors Trade OSIR After The Recent Volatility? Get Free Report Here
Cirrus Logic, Inc.(NASDAQ:CRUS) shares declined 3.79% to $20.31. The company on July 25 reported first-quarter profit of $20.64 million or $0.31 per share, up from $6.93 million or $0.10 per share in the same period last year. Revenues totaled $155.13 million, up from $99.01 million last year. Analysts expected revenues of $160.12 million.
Looking forward, the company has forecast second quarter revenues in the range of $170 million to $190 million. Analysts currently expect second-quarter revenues of $189.99 million.
How Should Investors Trade CRUS After The Recent Volatility? Get Free Report Here
JinkoSolar Holding Co., Ltd. (NYSE:JKS) shares jumped 4.87% to $14.21. The company, on August 14, announced its unaudited financial results for the second quarter ended June 30, 2013. Total revenues were RMB1.76 billion (US$287.6 million), representing an increase of 51.7% from the first quarter of 2013 and an increase of 42.6% from the second quarter of 2012. Net income attributable to JinkoSolar Holding Co., Ltd.'s ordinary shareholders was RMB49.0 million(US$8.0 million), compared with a net loss attributable to JinkoSolar Holding Co., Ltd.'s ordinary shareholders of RMB128.7 millionin the first quarter of 2013 and a net loss attributable to JinkoSolar Holding Co., Ltd.'s ordinary shareholders of RMB310.5 millionin the second quarter of 2012.
Is JKS A Good Buy After The Recent Price Movement? Find Out Here
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) shares dropped 1.06% and closed at $3.74. The company on August 8 announced its second quarter 2013 financial results. Net loss for the second quarter of 2013 was $30.3 million, or basic and diluted net loss per share available to common stockholders of $0.31, compared with net loss for the second quarter of 2012 of $20.1 million, or basic and diluted net loss per share available to common stockholders of $0.22. Collaboration revenues for the second quarter of 2013 were $18.5 million, compared to $12.1 million for the second quarter of 2012, an increase of $6.4 million, or 53%.
Is MACK A Strong Buy? Get Advantage Of Our Free Trend Analysis Here
Here at Winston we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. We focus on companies that we feel are trading at a discount to the market for various reasons. Enter your email and track our performance! We are sure you won’t be disappointed.
http://winstonsmallcap.com/and its owners, and their affiliates, directors and officers, and immediate family members, are hereafter collectively referred to as “WSC” or “we” or “us” or “our”). WSC publishes information (the “Information”) about publicly traded companies (the “Profiled Company” or the “Profiled Companies”) which has been obtained from various sources including publicly available sources on the internet. WSC does not undertake any due diligence or investigation of the Information it obtains or publishes.
Read Full Disclaimer at: http://winstonsmallcap.com/disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)